Kodiak Sciences Inc.
NASDAQ:KODBiotechnology
-$0.03 today
- Market cap
- $6.40B
- Beta
- 2.21
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$3.73
Volume 0.74M
Average 1.10M
KOD Total Current Liabilities
All obligations due within one year.
Kodiak Sciences Inc.NASDAQ: KOD
Total Current Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total current liabilities rises 29.0% from a year ago
Total current liabilities stood at $54.74M at the end of Q3 FY2026, up 29.0% from a year earlier and up 3.7% from the prior quarter. Over 3 fiscal years it compounded at -4.6% a year.
Context
- Total current liabilities amounted to 26.1% of total assets at the end of Q3 FY2026, up 6.7 pp from a year earlier.
- Total current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +29.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 45.53M USD
- Year-over-year change
- +78.1%
- 4-year CAGR
- -8.4%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 45.53M | +78.1% |
| FY2024 | 2024-12-31 | 25.57M | -38.7% |
| FY2023 | 2023-12-31 | 41.73M | -20.5% |
| FY2022 | 2022-12-31 | 52.5M | -18.8% |
| FY2021 | 2021-12-31 | 64.68M | — |
Total Current Liabilities vs competitors
How KOD compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +29.0% is the 4th highest of 9, against a peer median of +24.2%.
- Total current liabilities amounts to 26.1% of total assets for KOD, versus a peer median of 13.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $5.53B USD | +50.8% | +11.6% | 13.3% | |
| Jun 2026 | $1.89B USD | +2.7% | +14.0% | 13.6% | |
| Sep 2026 | $54.74M USD | +29.0% | -4.6% | 26.1% | |
| Mar 2026 | $47.68M USD | +25.7% | +17.4% | 6.5% | |
| Mar 2026 | CHF 43.73M CHF | +10.8% | +45.2% | 18.0% | |
| Mar 2026 | $43.4M USD | +61.4% | +40.9% | 8.5% | |
| Mar 2026 | $38.88M USD | +56.6% | +32.4% | 177.6% | |
| Mar 2026 | $37.46M USD | -10.1% | +2.3% | 13.0% | |
| Mar 2026 | $20.71M USD | +22.6% | -6.9% | 36.4% | |
BLTEBelite Bio, Inc | Jun 2026 | $14.95M USD | — | +67.5% | 1.9% |
| Peer median (excluding KOD) | — | +24.2% | +17.4% | 13.3% | |
Competitors are the stored peer set for KOD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 731.51M | 190.43M | 285.51M | 168.07M | 209.86M |
| Short-term Investments | 0 | 288.5M | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 3.3M | 7.07M | 3.8M | 3.86M | 4.95M |
| Total Current Assets | 734.81M | 486.01M | 289.31M | 171.94M | 214.82M |
| Property, Plant & Equipment (Net) | 108.07M | 115.75M | 175.02M | 148.73M | 121.86M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 6.32M | 6.32M | 6.32M | 6.18M | 6.18M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 55.01M | 58.55M | 8.72M | 8.73M | 8.67M |
| Total Non-current Assets | 169.41M | 180.62M | 190.06M | 163.64M | 136.72M |
| Total Assets | 904.22M | 666.63M | 479.37M | 335.58M | 351.53M |
| Account Payables | 12.43M | 9.13M | 13.61M | 3.92M | 12.86M |
| Short-term Debt | 3.93M | 9.93M | 9.77M | 0 | 12.06M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 42.13M | 27.41M | 12.27M | 0 | 12.84M |
| Total Current Liabilities | 64.68M | 52.5M | 41.73M | 25.57M | 45.53M |
| Long-term Debt | 99.94M | 100M | 100M | 0 | 100M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 211K | 162K | 0 | 100M | 1.5M |
| Total Non-current Liabilities | 176.22M | 177.97M | 171.86M | 159.72M | 148.62M |
| Total Liabilities | 240.9M | 230.46M | 213.59M | 185.29M | 194.15M |
| Common Stock | 5K | 5K | 5K | 5K | 6K |
| Retained Earnings | (558.22M) | (892.04M) | (1.15B) | (1.33B) | (1.56B) |
| Accumulated OCI | 0 | (1.31M) | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 663.32M | 436.17M | 265.78M | 150.29M | 157.38M |
| Total Debt | 179.94M | 187.73M | 181.63M | 70.35M | 159.18M |
| Net Debt | (551.57M) | (2.7M) | (103.88M) | (97.73M) | (50.68M) |
Kodiak Sciences Inc.
NASDAQ:KOD
Intrinsic Alpha fair value
Locked
Current Price
$97.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.